- Certain groups are at an increased risk for serious
complications from the flu, including adults 50 years of age and
older and those with chronic health conditions.
- Sanofi's two higher-dose influenza vaccines, Fluzone® High-Dose
Quadrivalent (Influenza Vaccine) and Flublok® Quadrivalent
(Influenza Vaccine), have shown better flu protection than
standard-dose flu shots in older adults.a,b
BRIDGEWATER, N.J., Sept. 13,
2023 /PRNewswire/ -- In collaboration with Ice-T,
Sanofi has debuted a trailer for this year's newest thriller –
The Season. The trailer taps into suspenseful movie
tropes to educate older adults, particularly those with chronic
health conditions, about the risks associated with the flu. The
Season serves as a powerful reminder about the importance of
higher-dose flu vaccines to help protect more vulnerable
populations from the flu and its related
complications.
The Season is part of a national flu vaccination campaign
from Sanofi and the American Society of Consultant
Pharmacists (ASCP), an organization that represents healthcare
professionals who are focused on the medication needs of older
adults. The campaign encourages older adults, particularly those
with one or more underlying health conditions, to speak with their
healthcare provider about flu vaccine options that may be right for
them, which may include Fluzone® High-Dose Quadrivalent
(Influenza Vaccine) or Flublok® Quadrivalent (Influenza
Vaccine).
Michael
Greenberg, MD, MPH
North America Medical Head of
Vaccines at Sanofi
"The flu can be a serious public health threat and lead to
complications such as heart attack, stroke, and pneumonia.
These can be especially dangerous for older adults, ethnic
and racial minority groups who are at an increased risk for being
hospitalized from the flu, and those living with chronic
conditions, like asthma, diabetes and heart disease. Our hope is
that, as a part of our annual commitment to educating the public
about the flu, this campaign will increase awareness of the
importance of flu vaccination and remind older adults and at-risk
populations that there are vaccines available to them that may
provide better protection for their specific needs, such as
Fluzone High-Dose Quadrivalent or Flublok
Quadrivalent."
The United States may face a
resurgence of flu this year. According to the U.S. Centers for
Disease Control and Prevention (CDC), preliminary results for the
2022-2023 season indicate approximately 70 per 100,000 people aged
18 and older were hospitalized for flu in the United
States. The rate was more than double in adults aged 65 and
older.
Chad Worz,
PharmD, BCGP, FASP
Executive Director and Chief
Executive Officer of ASCP
"Flu is unpredictable. Most of us already know that getting an
annual flu shot is important, but it is also critical for people to
understand which flu shots are most appropriate for them,
especially older adults. As a pharmacist, I see many people coming
in to get vaccinated who don't know which flu shot options are
available to them, and I want more people to feel empowered to talk
to their doctors or pharmacists about their options."
It's important for those who bear the greatest burden of the flu
– people age 65 years and older – to get vaccinated. Since 2010,
the CDC estimates that between 50% and 70% of seasonal flu-related
hospitalizations occurred in this age group.
Ice-T
Rapper/Actor
"As a rapper, actor, husband and father, I don't get a lot of
sick days, so it's critical for me to get my flu shot every year.
Now that I'm 65, I've learned that the flu can potentially cause
more complications for me, and that higher-dose flu shots may give
me better protection. This is why I am so excited to be partnering
with Sanofi so that I can help deliver this important public health
message."
Visit SanofiFluShots.com to learn more about the potential
complications associated with the flu, including heart attack,
stroke and pneumonia, and to learn more about Sanofi's Fluzone
High-Dose Quadrivalent (Influenza Vaccine) and Flublok Quadrivalent
(Influenza Vaccine). You can also see more content from The
Season here and share your support by using
#PrepareForTheSeason on your social channels.
About Fluzone® High-Dose
Quadrivalent (Influenza Vaccine) and Flublok®
Quadrivalent (Influenza Vaccine)
Flublok Quadrivalent and Fluzone High-Dose Quadrivalent are
indicated for immunization against disease caused by influenza A
and B strains contained in the vaccine. Flublok Quadrivalent is
given to people 18 years of age and older. Fluzone High-Dose
Quadrivalent is given to people 65 years of age and older.
aFluzone High-Dose Quadrivalent (Influenza Vaccine)
has been licensed for use in adults 65 years of age and older and
has demonstrated superior efficacy in a randomized controlled trial
versus a standard-dose Fluzone® (Influenza Vaccine) for
the prevention of laboratory-confirmed influenza illness.
Study Design: Based on a clinical trial of ~32,000 adults 65+
conducted during 2 flu seasons, 2011-2012 and 2012-2013, where an
influenza case was laboratory tested.
Compared with Fluzone, the most common side effects were
slightly more frequent and included pain and redness where you got
the shot, muscle ache, tiredness, and headache.
bFlublok Quadrivalent (Influenza Vaccine) has proven
to be 30% more effective than a Fluarix® Quadrivalent influenza
vaccine in preventing flu in adults 50+.
Study Design: Randomized, controlled clinical trial of ~9,000
adults 50+ conducted during 2014-2015 flu (or influenza)
season.
In adults 50 years of age and older, the most common side
effects were pain and/or tenderness at the injection site,
headache, and tiredness.
In 2022, the CDC's Advisory Committee on Immunization Practices
(ACIP) granted preferential recommendation for the use of Fluzone
High-Dose Quadrivalent (Influenza Vaccine), Flublok Quadrivalent
(Influenza Vaccine), and an adjuvanted flu vaccine for adults 65+.
If one of these three vaccines is not available at an opportunity
of vaccine administration, then any other age-appropriate
standard-dose influenza vaccine should be used.
All trademarks are the property of their respective owners.
Indication and Important Safety Information for
Flublok® Quadrivalent (Influenza Vaccine) and
Fluzone® High-Dose Quadrivalent (Influenza
Vaccine)
What are FLUBLOK® QUADRIVALENT (INFLUENZA
VACCINE) and FLUZONE® HIGH-DOSE QUADRIVALENT
(INFLUENZA VACCINE)?
Flublok Quadrivalent and Fluzone High-Dose Quadrivalent are
indicated for immunization against disease caused by influenza A
and B strains contained in the vaccine. Flublok Quadrivalent is
given to people 18 years of age and older. Fluzone High-Dose
Quadrivalent is given to people 65 years of age and
older.
IMPORTANT SAFETY INFORMATION FOR
FLUBLOK® QUADRIVALENT
(INFLUENZA VACCINE) and
FLUZONE® HIGH-DOSE
QUADRIVALENT (INFLUENZA VACCINE)
Flublok Quadrivalent and Fluzone High-Dose Quadrivalent should
not be given to anyone who has had a severe allergic reaction
(anaphylaxis) to any component of the vaccine (including eggs or
egg products for Fluzone High-Dose Quadrivalent). In addition,
Fluzone High-Dose Quadrivalent should not be given to anyone who
has had a severe allergic reaction after previous dose of any
influenza vaccine.
Tell your health care provider if you have ever had
Guillain-Barré syndrome (severe muscle weakness) after a previous
influenza vaccination.
If Flublok Quadrivalent and Fluzone High-Dose Quadrivalent are
given to people with a compromised immune system, including those
receiving therapies that suppress the immune system, the immune
response may be lower than expected.
Vaccination with Flublok Quadrivalent and Fluzone High-Dose
Quadrivalent may not protect all people who receive the
vaccine.
For Flublok Quadrivalent, in adults 18 through 49 years of age,
the most common side effects were tenderness, and/or pain where you
got the shot; headache, tiredness, muscle aches, and joint pain. In
adults 50 years of age and older the most common side effects were
tenderness, and/or pain where you got the shot; headache, and
tiredness.
For Fluzone High-Dose Quadrivalent, in adults 65 years of age
and older, the most common side effects were pain, redness, and/or
swelling where you got the shot; muscle aches, headache, and
general discomfort.
For Flublok Quadrivalent and Fluzone High-Dose Quadrivalent,
other side effects may occur.
For more information, talk to your health care professional and
refer to the full Prescribing Information for Flublok
Quadrivalent or Fluzone High-Dose Quadrivalent. Also, please
see complete Patient Information for Fluzone High-Dose
Quadrivalent.
About Ice-T
Ice-T has gained worldwide
recognition through his music, acting, multiple books and lecture
tour across America. In addition to being a multi
Grammy-winning artist, Ice-T has acted in a number of iconic roles,
including playing "Scotty Appleton"
in New Jack City and "Jack
Mason" in Surviving the Game. For his 24+ year
portrayal of "Sergeant Odafin 'Fin' Tutuola" in Law & Order:
Special Victims Unit, he won an NAACP Image Award.
Follow Ice-T on Instagram @IceT and
Twitter @FinalLevel.
About ASCP
ASCP is a membership association
that represents pharmacists, health care professionals, and
students serving the unique medication needs of older adults. ASCP
is an international organization with members located in all 50
states, Puerto Rico, and 12
countries. The society's mission is to promote healthy aging by
empowering pharmacists with education, resources, and innovative
opportunities.
Founded in 1969, ASCP is a 501(c)(6) non-profit organization
based in Alexandria, Virginia. The
ASCP Foundation is a 501(c)(3) non-profit organization; its purpose
is to carry out the charitable – including scientific, literary,
and educational – purposes of ASCP. Learn more about ASCP on their
website ASCP.com, on Facebook @ASCPharm, on LinkedIn
@ASCPharm or Instagram @ASCPharm.
About Sanofi
We are an innovative global healthcare company, driven by one
purpose: we chase the miracles of science to improve people's
lives. Our team, across some 100 countries, is dedicated to
transforming the practice of medicine by working to turn the
impossible into the possible. We provide potentially life-changing
treatment options and life-saving vaccine protection to millions of
people globally, while putting sustainability and social
responsibility at the center of our ambitions.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY.
Contacts
Evan Berland | + 1 215 432
0234 | evan.berland@sanofi.com
Investor Relations
Eva
Schaefer-Jansen | + 33 7 86 80 56 39
| eva.schaefer-jansen@sanofi.com
Arnaud Delépine | + 33 6 73 69 36 93
| arnaud.delepine@sanofi.com
Corentine Driancourt | + 33 6 40 56 92 21 |
corentine.driancourt@sanofi.com
Felix Lauscher | + 1 908 612 7239 |
felix.lauscher@sanofi.com
Tarik Elgoutni | + 1 617 710 3587
| tarik.elgoutni@sanofi.com
Nathalie Pham | + 33 7 85 93 30 17 |
nathalie.pham@sanofi.com
Sanofi Forward-Looking Statements
This press release
contains forward-looking statements as defined in the Private
Securities Litigation Reform Act of 1995, as amended.
Forward-looking statements are statements that are not historical
facts. These statements include projections and estimates and their
underlying assumptions, statements regarding plans, objectives,
intentions and expectations with respect to future financial
results, events, operations, services, product development and
potential, and statements regarding future performance.
Forward-looking statements are generally identified by the words
"expects", "anticipates", "believes", "intends", "estimates",
"plans" and similar expressions. Although Sanofi's management
believes that the expectations reflected in such forward-looking
statements are reasonable, investors are cautioned that
forward-looking information and statements are subject to various
risks and uncertainties, many of which are difficult to predict and
generally beyond the control of Sanofi, that could cause actual
results and developments to differ materially from those expressed
in, or implied or projected by, the forward-looking information and
statements. These risks and uncertainties include among other
things, the uncertainties inherent in research and development,
future clinical data and analysis, including post marketing,
decisions by regulatory authorities, such as the FDA or the EMA,
regarding whether and when to approve any drug, device or
biological application that may be filed for any such product
candidates as well as their decisions regarding labelling and other
matters that could affect the availability or commercial potential
of such product candidates, the fact that product candidates if
approved may not be commercially successful, the future approval
and commercial success of therapeutic alternatives, Sanofi's
ability to benefit from external growth opportunities, to complete
related transactions and/or obtain regulatory clearances, risks
associated with intellectual property and any related pending or
future litigation and the ultimate outcome of such
litigation, trends in exchange rates and prevailing interest
rates, volatile economic and market conditions, cost containment
initiatives and subsequent changes thereto, and the impact that
pandemics or other global crises may have on us, our customers,
suppliers, vendors, and other business partners, and the financial
condition of any one of them, as well as on our employees and on
the global economy as a whole. The risks and uncertainties
also include the uncertainties discussed or identified in the
public filings with the SEC and the AMF made by Sanofi, including
those listed under "Risk Factors" and "Cautionary Statement
Regarding Forward-Looking Statements" in Sanofi's annual report on
Form 20-F for the year ended December 31,
2022. Other than as required by applicable law, Sanofi does
not undertake any obligation to update or revise any
forward-looking information or statements.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/sanofi-and-rapperactor-ice-t-unveil-trailer-for-the-season-as-a-warning-against-the-flu-301925536.html
SOURCE Sanofi
